Aug 13, 2026 07:30AM
Jul 14, 2026 06:55AM
May 26, 2026 07:15AM
May 26, 2026 07:15AM
May 21, 2026 11:27PM
May 21, 2026 11:27PM
May 21, 2026 04:01PM NervGen announces public offering of shares and warrants
May 21, 2026 04:01PM
May 18, 2026 07:15AM
Apr 27, 2026 07:30AM
Apr 27, 2026 07:30AM
Apr 13, 2026 07:45AM
Apr 13, 2026 07:45AM
Apr 7, 2026 12:26PM NervGen receives FDA alignment on phase 3 trial for spinal cord injury drug
Apr 7, 2026 07:30AM
Apr 7, 2026 07:30AM
Apr 7, 2026 07:30AM
Mar 31, 2026 07:45AM
Mar 12, 2026 04:15PM
Mar 12, 2026 04:15PM
Mar 4, 2026 07:31AM NervGen hires Shamim Ruff as regulatory chief, Christine McSherry as SVP
Mar 4, 2026 07:30AM
Feb 18, 2026 07:30AM
Feb 12, 2026 04:15PM
Feb 12, 2026 04:15PM
Feb 11, 2026 07:00AM
Feb 9, 2026 07:00AM
Feb 9, 2026 07:00AM NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
Jan 20, 2026 07:00AM
Jan 8, 2026 06:30AM
Mar 25, 2025 08:30AM
Jul 28, 2022 10:38AM
Jan 10, 2022 07:30AM
Jul 9, 2019 10:52AM
Jun 10, 2019 07:00AM OTC Markets Group Welcomes NervGen Pharma to OTCQX
Jan 6, 2017 04:05PM

328,605 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All